Laura Lynne Asaro, NP
Nurse Practitioner · Boise
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Saint Alphonsus Regional Medical Center Inc · 672 clinicians in this group
Looking this up.
Hospitals listed: Saint Alphonsus Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Laura Lynne Asaro’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Saint Alphonsus Regional Medical CenterBoise, IDAcute Care Hospital · Voluntary non-profit - Church · Has an emergency department · Birthing-friendlyPart of Trinity Health, which runs 105 hospitals in 16 statesPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.685, Oct 2024 – Sep 2025
See every measure and the patient survey for Saint Alphonsus Regional Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.685 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.51 (0.61 to 2.4) · 1,246 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.76 to 1.29) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 198.88 (154.55 to 243.21) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.1 · 71 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.5 · 90 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 208 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 13.5 · 281 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 187 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.4 · 457 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.6 · 4,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.37) · 6,304 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.12 to 0.5) · 6,405 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.17 (1.41 to 4.93) · 2,394 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.15 (0.81 to 3.48) · 1,150 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.74 (1.41 to 4.06) · 2,265 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.21 (5.62 to 14.8) · 1,122 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.84 (2.81 to 8.86) · 1,099 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.98 (1.57 to 4.4) · 445 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.45 (0 to 1.07) · 5,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.2 · 60 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.69 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.783 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.603 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.896 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 12.9 · 378 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 454 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -9.3 · 249 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -5.1 · 305 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.2 · 185 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 14.4 · 327 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.9 (3.3 to 7.1) · 106 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.9 (7.2 to 13.1) · 106 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.9 · 63 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.7 · 85 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.5 · 174 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.5 to 18.6) · 276 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.3) · 967 cases | No different | Jan 2024 – Dec 2024 |
What patients said (970 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 83% |
| Patients who gave a rating of "9" or "10" (high) | 73% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 56% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
Original Medicare doctor bills
$23,761
Medicare paid this office $23,761 for 215 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 112 | $12,312 | $70 |
| Short return visit (20+ min) | 72 | $4,066 | $46 |
| Telephone medical discussion with physician, 11-20 minutes | 33 | $3,062 | $70 |
| Telephone medical discussion with physician, 21-30 minutes | 22 | $2,467 | $107 |
| Long return visit (40+ min) | 15 | $1,696 | $113 |
Who their Medicare patients are
215 Original Medicare patients in 2024. Average age 78 · Women 50% · Also on Medicaid 8% · Health risk score 2.15. Above the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: High blood pressure 73% · Cancer 58% · Coronary heart disease 28% · Chronic kidney disease 27% · Diabetes 24% · Heart failure 22% · Atrial fibrillation 21% · Depression 18% · COPD 14% · Stroke 9% · Dementia 7%.
The office billed $147,638, Medicare allowed $32,123 and paid $23,761; for 350 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 215 | 350 | 78 | 2.15 | $147,638 | $23,761 |
| 2023 | 179 | 605 | 77 | 1.86 | $276,248 | $45,476 |
| 2022 | 222 | 437 | 77 | 2.02 | $197,677 | $33,678 |
| 2021 | 141 | 327 | 78 | 2.40 | $126,606 | $24,255 |
| 2020 | 87 | 169 | 77 | 2.07 | $53,216 | $8,503 |
| 2018 | 208 | 327 | 77 | 1.88 | $62,524 | $13,261 |
| 2016 | 44 | 56 | 71 | 3.07 | $7,084 | $2,127 |
| 2015 | 132 | 300 | 72 | 2.05 | $36,205 | $12,908 |
| 2014 | 173 | 392 | 71 | 1.80 | $48,829 | $16,529 |
| 2013 | 159 | 292 | 72 | 2.04 | $39,391 | $12,597 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 5 services
| Return visit (30+ min) | 136 | $30,056 | $73 |
| Long return visit (40+ min) | 33 | $5,679 | $111 |
| Short return visit (20+ min) | 47 | $4,032 | $52 |
| Telephone medical discussion with physician, 21-30 minutes | 27 | $3,071 | $106 |
| Telephone medical discussion with physician, 11-20 minutes | 21 | $2,489 | $73 |
2022: 5 services
| Return visit (30+ min) | 190 | $25,026 | $74 |
| Long return visit (40+ min) | 31 | $3,686 | $115 |
| Telephone medical discussion with physician, 21-30 minutes | 24 | $2,471 | $103 |
| Telephone medical discussion with physician, 11-20 minutes | 15 | $1,267 | $75 |
| Short return visit (20+ min) | 15 | $740 | $49 |
2021: 4 services
| Return visit (30+ min) | 102 | $17,521 | $78 |
| Short return visit (20+ min) | 41 | $2,951 | $50 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,929 | $96 |
| Telephone medical discussion with physician, 11-20 minutes | 13 | $1,215 | $76 |
2020: 3 services
| Short return visit (20+ min) | 62 | $4,702 | $40 |
| Long return visit (40+ min) | 20 | $1,758 | $88 |
| Return visit (30+ min) | 17 | $1,304 | $62 |
2018: 3 services
| Short return visit (20+ min) | 174 | $10,067 | $36 |
| Long return visit (40+ min) | 22 | $1,782 | $81 |
| Return visit (30+ min) | 24 | $1,374 | $55 |
2016: 2 services
| Return visit (30+ min) | 13 | $813 | $51 |
| Return visit (30+ min) | 15 | $536 | $32 |
2015: 3 services
| Return visit (30+ min) | 70 | $7,685 | $49 |
| Short return visit (20+ min) | 75 | $3,696 | $31 |
| Long return visit (40+ min) | 16 | $1,424 | $71 |
2014: 3 services
| Return visit (30+ min) | 105 | $10,917 | $46 |
| Short return visit (20+ min) | 82 | $3,218 | $29 |
| Long return visit (40+ min) | 17 | $1,383 | $69 |
2013: 4 services
| Return visit (30+ min) | 89 | $6,090 | $48 |
| Long return visit (40+ min) | 41 | $3,755 | $66 |
| Short return visit (20+ min) | 66 | $2,145 | $27 |
| Short return visit | 12 | $139 | $12 |
Medicaid work
$297 in 2018
Medicaid paid $297 for 13 billed services this clinician did in 2018, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 13 | $297 |
| 2018 | 13 | 1 | 13 | $297 |
Drugs they prescribed that Part D paid
$645,324
Pharmacies billed $645,324 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 8% of their Part D prescriptions (33 of 397) in 2024. Above the middle of the specialty; the typical nurse practitioner clinician is at 0%.
332 generic and fewer than 11 brand-name prescriptions · $645,324 in drug cost · 14 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 17 | $17,533 | $1,031 |
| Ondansetron | 36 | $999 | $28 |
| Anastrozole | 22 | $779 | $35 |
| Dexamethasone | 14 | $376 | $27 |
| Diphenoxylate-Atropine | 11 | $215 | $20 |
See all 10 drugs
| Eliquis | 17 | $17,533 | $1,031 |
| Ondansetron | 36 | $999 | $28 |
| Anastrozole | 22 | $779 | $35 |
| Dexamethasone | 14 | $376 | $27 |
| Diphenoxylate-Atropine | 11 | $215 | $20 |
| Lorazepam | 24 | $151 | $6 |
| Metoclopramide | 24 | $77 | $3 |
| Pantoprazole | 12 | $52 | $4 |
| Prednisone | 16 | $38 | $2 |
| Zolpidem | 11 | $17 | $2 |
Year by year
| 2024 | 397 | 135 | 8% (33) | None | $645,324 |
| 2023 | 937 | 216 | 6% (59) | None | $1,116,774 |
| 2022 | 1,099 | 269 | 8% (91) | 20% | $1,648,089 |
| 2021 | 928 | 200 | 11% (101) | None | $1,149,580 |
| 2020 | 422 | 126 | 8% (34) | 14% | $418,217 |
| 2019 | 48 | 23 | None | 35% | $4,867 |
| 2018 | 173 | 85 | 22% (38) | 8% | $7,614 |
| 2017 | 168 | 79 | 64% (108) | 15% | $14,443 |
| 2016 | 97 | 36 | None | None | $2,838 |
| 2015 | 440 | 122 | 18% (80) | None | $147,524 |
| 2014 | 506 | 149 | 25% (128) | 8% | $111,755 |
| 2013 | 328 | 102 | 24% (79) | 11% | $111,011 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Ibrance | 15 | $240,234 | $16,016 |
| Eliquis | 35 | $23,190 | $663 |
| Xarelto | 21 | $20,892 | $995 |
| Exemestane | 16 | $4,143 | $259 |
| Erlotinib | 12 | $3,258 | $271 |
| Ondansetron | 71 | $1,678 | $24 |
| Oxycodone | 11 | $1,357 | $123 |
| Megestrol Acetate | 21 | $1,281 | $61 |
| Pantoprazole | 41 | $1,262 | $31 |
| Potassium Chloride | 31 | $1,182 | $38 |
| Dexamethasone | 35 | $903 | $26 |
| Anastrozole | 19 | $711 | $37 |
| Hydrocodone-Acetaminophen | 24 | $472 | $20 |
| Lorazepam | 64 | $392 | $6 |
| Amlodipine Besylate | 17 | $330 | $19 |
| Diphenoxylate-Atropine | 19 | $277 | $15 |
| Rosuvastatin | 12 | $263 | $22 |
| Metoclopramide | 52 | $202 | $4 |
| Prednisone | 40 | $154 | $4 |
| Atorvastatin | 11 | $124 | $11 |
| Triamcinolone Acetonide | 13 | $112 | $9 |
| Furosemide | 14 | $107 | $8 |
| Famotidine | 12 | $63 | $5 |
2022: 26 drugs
| Tibsovo | 13 | $380,367 | $29,259 |
| Imbruvica | 13 | $193,981 | $14,922 |
| Ibrance | 11 | $171,116 | $15,556 |
| Erlotinib | 16 | $36,587 | $2,287 |
| Xarelto | 38 | $35,006 | $921 |
| Eliquis | 40 | $26,854 | $671 |
| Vemlidy | 11 | $13,864 | $1,260 |
| Ondansetron | 87 | $2,126 | $24 |
| Potassium Chloride | 29 | $1,730 | $60 |
| Pantoprazole | 45 | $987 | $22 |
| Oxycodone | 17 | $713 | $42 |
| Anastrozole | 27 | $700 | $26 |
| Tamoxifen Citrate | 11 | $554 | $50 |
| Dexamethasone | 28 | $536 | $19 |
| Ondansetron Odt | 13 | $444 | $34 |
| Hydrocodone-Acetaminophen | 33 | $375 | $11 |
| Nystatin | 22 | $358 | $16 |
| Triamcinolone Acetonide | 14 | $334 | $24 |
| Lorazepam | 59 | $320 | $5 |
| Levothyroxine | 12 | $237 | $20 |
| Metoclopramide | 60 | $215 | $4 |
| Amlodipine Besylate | 16 | $181 | $11 |
| Furosemide | 29 | $176 | $6 |
| Prednisone | 28 | $162 | $6 |
| Allopurinol | 13 | $110 | $8 |
| Trazodone | 13 | $91 | $7 |
2021: 26 drugs
| Lenvima | 13 | $265,458 | $20,420 |
| Imbruvica | 11 | $151,802 | $13,800 |
| Vemlidy | 13 | $15,517 | $1,194 |
| Xarelto | 19 | $12,296 | $647 |
| Eliquis | 13 | $9,218 | $709 |
| Enoxaparin | 14 | $4,709 | $336 |
| Potassium Chloride | 19 | $2,110 | $111 |
| Ondansetron | 76 | $1,753 | $23 |
| Anastrozole | 15 | $575 | $38 |
| Hydrocodone-Acetaminophen | 36 | $549 | $15 |
| Dexamethasone | 21 | $545 | $26 |
| Levothyroxine | 22 | $519 | $24 |
| Lorazepam | 57 | $345 | $6 |
| Hydroxyurea | 17 | $323 | $19 |
| Pantoprazole | 26 | $269 | $10 |
| Hydromorphone | 11 | $215 | $20 |
| Nystatin | 12 | $212 | $18 |
| Oxycodone | 12 | $196 | $16 |
| Zolpidem | 24 | $187 | $8 |
| Furosemide | 22 | $187 | $9 |
| Prednisone | 23 | $185 | $8 |
| Tamsulosin | 18 | $180 | $10 |
| Metoclopramide | 41 | $130 | $3 |
| Amlodipine Besylate | 18 | $109 | $6 |
| Ibuprofen | 11 | $76 | $7 |
| Tramadol | 11 | $28 | $3 |
2020: 8 drugs
| Ondansetron | 38 | $989 | $26 |
| Hydrocodone-Acetaminophen | 19 | $381 | $20 |
| Levothyroxine | 16 | $328 | $20 |
| Potassium Chloride | 13 | $297 | $23 |
| Lorazepam | 47 | $175 | $4 |
| Tamsulosin | 12 | $174 | $14 |
| Dexamethasone | 12 | $156 | $13 |
| Metoclopramide | 23 | $97 | $4 |
2018: 4 drugs
| Oxycodone | 18 | $345 | $19 |
| Anastrozole | 17 | $274 | $16 |
| Prochlorperazine Maleate | 24 | $187 | $8 |
| Prednisone | 14 | $67 | $5 |
2017: 3 drugs
| Oxycodone-Acetaminophen | 30 | $1,022 | $34 |
| Oxycodone | 44 | $944 | $21 |
| Gabapentin | 14 | $231 | $16 |
2016: 1 drug
| Anastrozole | 23 | $304 | $13 |
2015: 11 drugs
| Anastrozole | 48 | $1,605 | $33 |
| Hydrocodone-Acetaminophen | 41 | $1,045 | $25 |
| Hydroxyurea | 23 | $802 | $35 |
| Oxycodone | 11 | $210 | $19 |
| Spironolactone | 12 | $110 | $9 |
| Prochlorperazine Maleate | 16 | $105 | $7 |
| Gabapentin | 12 | $96 | $8 |
| Prednisone | 15 | $95 | $6 |
| Amlodipine Besylate | 14 | $75 | $5 |
| Alprazolam | 11 | $56 | $5 |
| Citalopram Hbr | 16 | $46 | $3 |
2014: 14 drugs
| Anastrozole | 76 | $4,407 | $58 |
| Doxycycline Hyclate | 11 | $1,995 | $181 |
| Hydrocodone-Acetaminophen | 52 | $1,057 | $20 |
| Hydroxyurea | 18 | $689 | $38 |
| Morphine Sulfate Er | 16 | $570 | $36 |
| Oxycodone | 18 | $439 | $24 |
| Ondansetron Odt | 12 | $369 | $31 |
| Tamsulosin | 11 | $228 | $21 |
| Gabapentin | 19 | $219 | $12 |
| Lorazepam | 14 | $105 | $8 |
| Prochlorperazine Maleate | 15 | $90 | $6 |
| Tramadol | 16 | $60 | $4 |
| Alendronate | 12 | $53 | $4 |
| Lisinopril | 11 | $49 | $4 |
2013: 6 drugs
| Gleevec | 11 | $61,991 | $5,636 |
| Anastrozole | 42 | $3,315 | $79 |
| Hydroxyurea | 15 | $659 | $44 |
| Hydrocodone-Acetaminophen | 24 | $356 | $15 |
| Tamoxifen Citrate | 15 | $185 | $12 |
| Omeprazole | 15 | $100 | $7 |
Money from drug and device companies
$71 in 2025
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $43 | 1 payment
|
| Janssen Biotech | Talvey | $28 | 1 payment
|
See all 2 published payments
| AstraZeneca Pharmaceuticals LP | Education · 2025-11-25 | Enhertu | $43 |
| Janssen Biotech | Meals · 2025-04-04 | Talvey | $28 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 83.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1003916636
- Licence
- CA 95010735, MA RN2319223
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- ID 807569400, MA 110132668A
- Taxonomy
- Nurse practitioner (363L00000X); Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 875 Blake Wilbur Dr, Clinic D, Stanford, CA, 94305
- NPI first listed
- 2006-09-24
- NPI last updated
- 2025-02-03
- NPI record certified
- 2025-02-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 800 Washington St, Boston, MA, 02111 · 4400 E Flamingo Ave Ste 130, Nampa, ID, 83687 · 1050 Sw 3rd Ave Ste 220, Ontario, OR, 97914 · 41 Montvale Ave Ste 550, Stoneham, MA, 02180